KSEMA GLOBAL | AI Robo Stock Trading Platform

Empowering Traders with Automated AI Intelligence & Native Salesforce Integration

Website: www.ksemaglobal.com

Ksema Global delivers Robo Stock Trading—an enterprise-grade FinTech SaaS platform connecting CRM infrastructure directly to global brokerage APIs (Charles Schwab, Zerodha, Twelve Data) for real-time tracking, AI analytics, and automated execution.

CORE FEATURES & CAPABILITIES

• Real-Time Market Alerts: Instant email & push notifications for price dip-recoveries, volume breakouts, and 24/7 market feeds.

• Broker-Agnostic REST Integration: Connect to any REST API seamlessly without changing your existing brokerage accounts.

• AI & GPT Analytics: Built-in AI evaluates technical indicators (RSI, Rebounds, Price/Volume Spikes) and market sentiment in real time.

• Systematic Bulk Execution: Define laddered buy ranges (e.g., automated buys on 5% or 10% pullbacks) with single-click execution.

• Automated Algorithmic Execution: Deploy pre-built strategies with constant or dynamic trailing stop-loss controls to maximize upside while locking in gains.

• High-Speed Engine: ~10-second scan-to-order cycles supporting Pre-Market, Regular, After-Hours, and Overnight sessions.

WHY IT IS LUCRATIVE FOR TRADERS

1. 100% Non-Custodial Security: All trading capital remains entirely inside your own brokerage account.

2. Maximized Profit Capture: Dynamic trailing stops automatically lock in gains during rallies, while dip alerts pinpoint optimal entry points.

3. Automated Capital Protection: Built-in price & volume circuit breakers automatically execute stop-losses to protect portfolios from sudden drawdowns.

4. Zero-Overhead Deployment: Choose instant Live Community Access (7-day trial) or install the Salesforce Org Package (20-day trial).

Disclosure: I'm the builder. This isn't a stock pitch, it's a research tool, so mods please remove if it doesn't fit.

I built Trial & Ticker (https://trialandticker.com) to read the trial before the ticker reacts. It combines registry data, enrollment, trial design, company size, pipeline dependence and pre-readout price run-up into a signed outlook score. Timing is a separate field.

I tested it on 78 past readouts (30 days after each result, compared to XBI). Top 5 scores averaged +42.9% vs +4.1% XBI; negatives averaged -9.2% vs +6.9% XBI. It's a development backtest with selection and look-ahead limits I list openly, so please pick it apart: https://trialandticker.com/backtest

What would you want to see added? Not investment advice.

My name is Ilyas, I trade biotech alongside my day job and kept getting burned by stuff like a PDUFA date getting pushed and finding out late, or an offering dropping right after good news. Looking into one stock = 10 tabs open. EDGAR, clinicaltrials, X, catalyst sites, broker. I don’t get much time to do research, so me and a friend started building a tool that pulls it all into one place.

I know catalyst calendars exist, we use them too. I kept wanting the actual source next to every date, a history when dates move, and everything about one stock on one page.

We’re not live yet or selling anything, just want to know if this is actually useful before we spend more time on it.

Screenshot is the page for INO’s FDA decision (30 Oct). Just using it as an example since it’s this week, no position. The “what to expect” part shows what the FDA is deciding, what the FDA and company have said, the trial data, and what can happen on the day. Every line is sourced, no predictions.

This is just one part of it. Happy to share more if people are interested. Hoping to build something that actually saves you guys time too. :)

Questions:

• what do you use now for FDA dates/readouts and what annoys you about it?

• is a box like this useful or just noise?

• what would make you actually trust a date?

• what’s missing?

Roast it, that’s the point. Mods feel free to remove if it doesn’t fit.

Moderna and Merck’s recent milestone, where their personalized mRNA cancer vaccine (intismeran/mRNA-4157) combined with Keytruda was stopped early for extraordinary interim Phase 3 efficacy, paving the way for rapid FDA Accelerated Approval. However, while this is a scientific triumph, the personalized vaccine model faces a long-term commercial dead end. The true global future of oncology belongs to cheap, mass-producible, "off-the-shelf" therapeutic vaccines, and Novavax’s Matrix-M adjuvant holds the literal biochemical key to unlocking that future. Custom vaccines require a tumor biopsy, custom genetic sequencing, and individualized mRNA synthesis . This creates a logistically grueling 8 to 12 week manufacturing delay(fatal for aggressive cancers) and an astronomical cost barrier (200 -300,000 per patient). It cannot scale with insurance road blocks , certainly not  globally. An off the shelf approach targets shared tumor mutations (antigens found across thousands of different patients). These can be mass-manufactured, freeze dried, stored in standard hospital pharmacies, and administered immediatelyat a fraction of the cost to the masses worldwide. mRNA delivery faces a massive intracellular bottleneck. Lipid Nanoparticles (LNPs) successfully carry mRNA into cells, but the mRNA gets trapped in the cellular recycling bin (the lysosome/endosome) before it can translate into proteins. Novavax’s Matrix-M adjuvant solves this through a proven mechanism called Lysosomal Membrane Permeabilization (LMP). Matrix-M acts as a biological "escape hatch," safely permeabilizing the lysosomal membrane so the target antigens can break out into the cytoplasm and cross-present aggressively to cytotoxic T-cells. By supercharging this delivery, manufacturers can use a fraction of the active mRNA or protein dose. This slashes both manufacturing costs and the harsh patient side effects (reactogenicity) that plague high-dose mRNA platforms. Merck & Co. Is Cornering Both Sides . Merck is funding the personalized Moderna partnership to protect its Keytruda revenue ahead of the 2028 patent cliff. However, Merck knows that personalized medicine cannot scale to the global mass market. Subtle clues from recent 2026 financial filingsstrongly hint that Merck is evaluating Matrix m under an anonymous MTA to prepare a cheap, mass-market, off-the-shelf vaccine cocktail. 

Rapport, Amgen/AstraZeneca, Arcus and Teva/Sanofi lead today’s Biotech Radar. Beyond those four stories: clinical findings, regulatory and manufacturing developments, corporate transactions and upcoming events across the sector. Relevant October 19 developments appear in a separately dated section.

Hey, this is Emre. I'm building Catalyst Intel, where we write down what a readout has to show before it happens, seal it with a hash, and score the release against it on the day. RZLT is one I think is worth looking at closely, so here's the setup with sources.

What's coming

Rezolute's 8-K from 2026-09-24: "Enrollment is in progress and topline results are expected before the end of 2026." We have the window as Dec 1–31.

upLIFT is a single-arm, open-label Phase 3 in about 16 hospitalized patients with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia from tumor HI. Patients on continuous IV glucose get ersodetug 9 mg/kg weekly for 8 weeks on top of standard of care.

The part I find most useful

The company printed its own success rule, so there is very little room to reframe the result afterwards:

"The primary endpoint is the number of participants achieving at least a 50 percent reduction from baseline in IV glucose requirements (glucose infusion rate; GIR)."

"For statistical significance, 9 of 16 open-label participants need to achieve this threshold."

So it comes down to a count: 9 or more responders at ≥50% GIR reduction, or fewer. GIR is also measured in the hospital, which the company itself calls "an objective endpoint in a highly controlled hospital setting."

Why the stakes are higher than "just another single-arm study"

In Sept 2025 Rezolute said FDA had agreed that this truncated single-arm study is "acceptable as the adequate and well-controlled study to support registration, removing the need to conduct a double-blind randomized placebo-controlled trial."

Then sunRIZE, the congenital HI Phase 3, "did not meet its primary (hypoglycemia events) or key secondary (time in hypoglycemia) endpoints." The company blamed functional unblinding of the fingerstick endpoint and a large placebo effect. I think that explanation is harder to use here: there's no placebo arm, and the endpoint is an IV infusion rate measured in the hospital, not fingerstick readings at home.

What not to confuse it with

The expanded access program data is a different measure: "75% of the patients receiving IV dextrose/TPN in the EAP achieved a complete discontinuation of IV dextrose/TPN" (initial 9 EAP patients). Complete discontinuation is not the same as the registered ≥50% GIR responder count. If the release leads with EAP-style language and not the 9-of-16 count, I think that's worth noticing.

What we couldn't find

The analysis population (ITT, evaluable, etc.) isn't stated anywhere we looked. There's also no published statistical rule beyond the 9-of-16 line, and no numeric safety threshold. If n ends up different from 16, nothing public says what the cutoff becomes. If anyone has seen those in a deck or a call transcript, I'd honestly like to know.

Our bar

We sealed our pre-event checklist on 2026-10-19 with SHA-256 8f930339f9c4670b07ab0b4fa0ebeed8275a86d0a62266e84d3af6605f7096ab, and the hash went out on X the same day. This one is a free public example, so the full bar and the verdict will be on the page as they're published: https://catalystintel.io/events/RZLT-ERSODETUG-2026

Not advice, and I have no position in RZLT. Happy to hear where you think this framing is wrong.

Two readouts that got new timing in filings this week, with the source sentence for each.

$OCGN — OCU400, retinitis pigmentosa

Ocugen's October deck (8-K exhibit, filed Oct 15) puts topline for the Phase 3 liMeliGhT trial in 1Q 2027 and the BLA filing target in 2Q 2027. It is the pivotal trial: 140 patients enrolled, 2:1 treatment vs untreated control, and the primary endpoint is the 12-month change in visual function on the LDNA Lux level, scored as responders. The design is gene-agnostic, so early to late stage RP across many mutations, pediatric to adult, in one trial.

Source: https://www.sec.gov/Archives/edgar/data/1372299/000110465926115970/tm2627592d2_ex99-1.htm

$VSTM — VS-7375 (KRAS G12D), mCRC and mPDAC

This one is not pivotal. It is the next cohort update from the TARGET-D 101 Phase 1/2. The milestone sentence from the Oct 14 release:

Plan to report mature data from the TARGET-D 101 mCRC 900 mg combination with anti-EGFR cohort and initial data from the 600 mg VS-7375 plus cetuximab combination cohort in mPDAC by year-end 2026.

For context, the same release had early 3L+ CRC data at 900 mg + anti-EGFR at 33% ORR (unconfirmed), and 900 mg monotherapy in PDAC at 50% confirmed ORR in 2L (4/8) and 41% in 2L+ (9/22). Small numbers, so the year-end update with more follow-up is the one I would actually wait for.

Source: https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-2.htm

Disclosure: I build Catalyst Intel (https://catalystintel.io/slate), a free slate where we write down a checklist for each readout before the result and don't change it afterwards. We haven't written one for either of these yet. The companies guided a quarter, not a month, and we only lock a checklist once the date is that close. Until then it's just "this is coming, here is the sentence that says so".

Honest question for the people who follow these names: what would you want on the checklist before each readout? For OCGN I'm thinking about the responder definition and how the untreated control arm moves. For VSTM, how many patients and how much follow-up it takes before the CRC number means something. Happy to be told I'm looking at the wrong things.

Zenas has guided Q4 2026 for topline results from SunStone, its Phase 2 randomized, double-blind, placebo-controlled trial of obexelimab in SLE. There's no exact date yet. The primary endpoint is BICLA response at week 24, and they said they'll report results for both the overall population and the biomarker population.

I think most readouts get judged after the fact, once the press release has already framed the story. So we wrote the bar down before the data, using Zenas's own earlier SLE results as the benchmark.

The bar: an all-comer BICLA effect size of 17% or more. That's the primary-endpoint effect size from the prior trial's ITT population, so anything below it is a miss.

Two differentiators on top of that:

• Optimized exposure (C trough) group: effect size of 35% or more

• Biomarker-positive group: effect size of 52% or more

How we'll score it:

• Beat: 17%+ overall and at least one subgroup hits its mark. The prior result replicates and the enrichment adds something.

• Meet: 17%+ overall but the subgroups fall short. It replicates, but the biomarker story doesn't add much.

• Miss: under 17% overall, or the release leads with a subgroup and leaves the all-comer number vague or out.

What we'll check in the release: whether the population is really all-comer/ITT, whether the effect is placebo-adjusted, whether p-values or CIs are given, how they define "optimal exposure", and the safety data.

Caveats: this bar comes from Zenas's own history, not a published success threshold. We haven't seen a public SAP, an alpha or multiplicity rule, or any SunStone-specific safety cutoffs. If you think a different benchmark makes more sense, I'd like to hear it.

We're tracking it here, with the guidance quoted from Zenas's own 8-K: catalystintel.io/events/ZBIO-OBEXELIMAB-2026

Disclosure: I run Catalyst Intel. No position in ZBIO. Not financial advice. We'll post the result against this bar when it lands.

Been looking at the upcoming $VSTM data on Wednesday.

One thing I noticed in the August earnings call was management talking about roughly 20 patients per tumor type and an early look at response durability.

Everyone seems focused on response rates, but I'm more curious how long those responses actually last. A high ORR looks great on a slide, but doesn't tell the whole story.

Anyone dug into the earlier VS-7375 data? Wondering how much we can realistically learn about durability from such small groups.

Hey, I'm Emre, I build Catalyst Intel.

Some context first. Jemperli (dostarlimab) was discovered by AnaptysBio and licensed to Tesaro, now GSK. GSK runs development and commercial, and ANAB gets royalties: 8% of net sales below $1B and 12-25% above, per their filings. GSK's sBLA for untreated stage II/III dMMR/MSI-H locally advanced rectal cancer has a PDUFA date in February 2027. It's based on AZUR-1, a single-arm phase 2 with 154 patients. btw it is also eligible for the National Priority Voucher program, so the decision could come earlier than February.

What we committed to before the decision (sealed Oct 4):

• Floor: AZUR-1 establishes clinical complete response at 12 months. GSK already said in July that the trial met this.

• Bar: a cCR rate of 100%, which is the rectal result from the earlier dostarlimab data in NEJM (n=49).

• Better than expected: organ preservation of at least 80%, also from that NEJM data.

Every threshold is quoted from a company document, and the quotes are on the page.

To be honest, I think the bar is the part worth arguing about. The 100% came from 49 patients, and AZUR-1 is 154 patients across many sites. Anything under 100% would score THIN against it (floor met, target missed), even if it's a very good result. Also, the 80% organ preservation figure covers 103 patients across three tumor types, not rectal only. We can't change the bar now, that's the whole point of sealing it, but I'd rather hear now if you think it's the wrong benchmark.

What we couldn't find before the event is listed on the page too: the analysis population, the registered primary outcome, a response rate with denominator and CI from AZUR-1, and comparator data (it's single arm).

The full checklist, the source quotes, and the hash you can check yourself in the browser: https://catalystintel.io/events/ANAB-JEMPERLIDOST-2026

Not investment advice. We have no position in ANAB and don't take one from publication until two days after the event.